A buyout of the Vyera contract seems to me to like
Post# of 145836
As you said, blafarm:
Quote:
as Dr.NP noted, the Vyera pricing structure presents a problem. The big question is -- if Vyera pricing precludes piecemeal partnering and licensing of individual indications, then what exactly are they talking about with those 11 Big Pharma companies?
Maybe there has been some interest by licensing partners in buying out the Vyera contract. With Vyera having the FTC lawsuit and possibly a subsequent huge financial penalty hanging over their head I could see them taking the easy cash/stock.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)